Introduction
============

Breast cancer is the most common malignancy among females in both developing and developed countries, with over 1.3 million cases diagnosed annually.[@b1-ott-7-543],[@b2-ott-7-543] With a more comprehensive understanding of the cancer and new protocols for treatment, the outcome of breast cancer patients has improved in the past few decades. However, breast cancer still remains the fifth leading cause of overall cancer deaths and the most frequent cause of cancer deaths in women.[@b1-ott-7-543],[@b2-ott-7-543] Identifying potential biomarkers that could serve as prognostic factors for breast cancer patients is crucial for individual treatment. Several biomarkers have been demonstrated to affect the survival of breast cancer patients so far, including P27,[@b3-ott-7-543] vascular endothelial growth factor (VEGF),[@b4-ott-7-543] cyclooxygenase-2 (COX-2),[@b5-ott-7-543] B cell lymphoma 2 protein (BCL-2),[@b6-ott-7-543] and cyclin D1.[@b7-ott-7-543]

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway plays a key role in cell growth, protein translation, autophagy, metabolism, and cell survival;[@b8-ott-7-543]--[@b10-ott-7-543] thus, tight regulation of the pathway is paramount to ensure that cellular inputs are integrated for appropriate cellular outcomes. To date, alternations in the components of the signaling pathway, including activating mutations of the p110α catalytic subunit of PI3K (*PI3KCA)* and phosphatase and tensin homolog loss, have been identified in a wide spectrum of human cancers.[@b11-ott-7-543],[@b12-ott-7-543] The mutations of *PIK3CA* have been reported in 8%--40% of breast cancer patients,[@b13-ott-7-543]--[@b22-ott-7-543] while the vast majority, comprising approximately 90% of cases, are clustered at two hot-spot regions in exon 9 and exon 20, which encode the helical and kinase domains, respectively.[@b14-ott-7-543],[@b21-ott-7-543]--[@b23-ott-7-543] Obviously, *PIK3CA* mutations are among the most common genetic aberrations in human breast cancer, and their relationship with clinicopathologic characteristics has been reported. Generally, the mutations are more frequent in estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative patients,[@b13-ott-7-543]--[@b16-ott-7-543],[@b18-ott-7-543],[@b20-ott-7-543],[@b24-ott-7-543]--[@b26-ott-7-543] but the data are not consistent. Controversy also exists concerning the prognostic value of *PIK3CA* mutations. Some researchers reported that the mutations correlated with favorable outcome,[@b14-ott-7-543]--[@b17-ott-7-543] while others reported the opposite results.[@b27-ott-7-543]--[@b30-ott-7-543] Moreover, some authors discovered a difference in prognostic values of mutations in exon 9 and exon 20.[@b13-ott-7-543],[@b28-ott-7-543],[@b30-ott-7-543]

With the aim to clarify the association between *PIK3CA* mutations and prognosis of breast cancer patients, we conducted the first comprehensive meta-analysis of published literature on this topic in patients with operable primary breast cancer and evaluated the prognostic value of *PIK3CA* mutations on disease-free survival (DFS) and overall survival (OS). To gain better insight into the underlying mechanism of the relationship, we conducted subgroup analyses of mutations in exon 9 and exon 20 of *PIK3CA*.

Materials and methods
=====================

Literature search
-----------------

A comprehensive, computerized literature search of PubMed, Web of Science databases, the Chinese Biomedical Literature Database, and Wangfang Data until August 27, 2013 was carried out. Potentially relevant studies were identified using breast cancer (ie, "breast cancer", "breast carcinoma", "breast neoplasm") and *PIK3CA* (ie, "phosphoinositide-3-kinase catalytic, alpha polypeptide", "PI 3-kinases catalytic, alpha polypeptide", "*PI3KCA*") groups of search terms. The reference lists from relevant papers, especially from review articles, were checked to identify studies overlooked in the original search. This systematic review and meta-analysis was planned, conducted, and reported in adherence to the standards of quality for reporting meta-analyses.[@b31-ott-7-543] A flow-chart of the literature search, study selection, and results of each step is presented in [Figure 1](#f1-ott-7-543){ref-type="fig"}.

Eligibility criteria
--------------------

All the citations from the initial search were subsequently screened for eligibility. Studies meeting all of the following inclusion criteria were deemed eligible and included in the analysis: 1) study was published in English; 2) study explored the relation between *PIK3CA* mutations and clinical outcome of operable primary breast cancer; 3) the outcomes to assess prognosis could be presented as one or more of the following: OS, DFS, metastasis-free survival (MFS), relapse-free survival, time to distant metastasis, and breast cancer-specific survival (BCSS); and 4) hazard ratio (HR) with 95% confidence intervals (CIs) (or sufficient data by which these could be calculated) was reported. All studies not satisfying the inclusion criteria and the data obtained from review, animal experiments, or cell line studies were excluded.

Study quality was assessed using the Newcastle-Ottawa Scale.[@b32-ott-7-543]

Data extraction and outcomes
----------------------------

Two reviewers (YZJ and YRL) independently assessed studies for inclusion, and disagreements were resolved by discussion between the two. If these two reviewers could not reach a consensus, a third reviewer (KDY) was consulted to resolve the dispute and a final decision was made by the majority of votes. The following information about each eligible study was recorded: first author names; journal and year of publication; patient nationality; total number of patients studied for *PIK3CA* mutations; median age of patients (with range, if possible) at diagnosis; the stage or type of breast cancer; treatment protocols (besides mastectomy, lumpectomy, or any other kind of breast cancer surgery); median follow-up time (with range, if possible); number of *PIK3CA*-mutant patients; number of mutations in exon 9 or 20; the percentage of ER+ and HER2+ patients with *PIK3CA* mutations; and the clinical outcomes with HR and 95% CI. MFS, PFS, breast cancer-specific survival, or time to distant metastasis in most studies had the same or similar definition to DFS, thus were treated as DFS when appropriate. When both the univariate and multivariate analyses were conducted, only the result of the latter is included in the present study.

Statistical analysis
--------------------

Heterogeneity between studies was evaluated by *Q*-test and *I*^2^, and either a *P*-value\<0.10 or *I*^2^\>50% was considered statistically significant. The pooled HR was estimated using the fixed effects model unless heterogeneity was found and was unexplainable, in which situation, the random effects model was applied. As different prognostic values of exon 9 and exon 20 mutations were reported, HR was also evaluated for each type of mutation. Sensitivity analysis was performed by omitting one study at a time to check if the inclusion criteria affected the final results. Potential bias of publication was examined by using the Begg's funnel plot and Egger's linear regression test (*P*\<0.05 considered to be statistically significant). All statistical analysis performed in this study was carried out using Stata software (v 12.0; StataCorp LP, College Station, TX, USA).

Results
=======

The process of the literature search and the result of each step are presented in [Figure 1](#f1-ott-7-543){ref-type="fig"}. One thousand one hundred and eighty studies were identified in the primary literature search, of which 26 potentially relevant studies were further evaluated after review of their titles and abstracts. A total of eight studies were included in this study according to the inclusion criteria.[@b13-ott-7-543]--[@b20-ott-7-543] The main characteristics of the eligible studies, all of which were retrospective cohort studies, are shown in [Table 1](#t1-ott-7-543){ref-type="table"}. The analyzed studies were published between 2007 and 2013. Six studies reported the results of outcome analysis of pooled mutations in exon 9 or exon 20 with HR and 95% CI (or sufficient data by which these could be calculated),[@b14-ott-7-543]--[@b19-ott-7-543] while four studies analyzed mutations in exon 9, and three studies reported mutations in exon 20. One study contained three subsets with a total of 1,352 patients for *PIK3CA* mutations, but only 342 patients with untreated lymph node-negative breast cancer were studied for the relationship between *PIK3CA* mutations and MFS.[@b20-ott-7-543]

The mutation rates of *PIK3CA* in breast cancer patients from retrieved studies ranged from 25.7%--33.4%. Of the eight studies analyzed, six presented more mutations in exon 20 than in exon 9 (45.8%--65.6% versus 28.1%--42.8%), but two reported the opposite results (30.4%--46.7% versus 53.3%--69.6%). Data associated with the percentage of ER+ and HER2+ patients with *PIK3CA* mutations were also recorded. Six of the eligible studies showed that *PIK3CA*-mutant tumors were more likely to be ER+ and HER2−, while the remaining two eligible studies focused on a specific subset of tumors (one on ER+ HER2−, the other on HER2+).

[Figure 2A](#f2-ott-7-543){ref-type="fig"} presents the forest plot of meta-analysis for OS and DFS, including HRs, 95% CIs, and the weight of each study in the analysis. As the heterogeneity between studies was not statistically significant (*I*^2^=0.0%; *P*=0.538), the fixed effects model was applied. The combined HR was 0.72 (95% CI: 0.57--0.91; *P*=0.006). To further test the robustness of our study, we performed sensitivity analysis by omitting one study each time. We found that no single study altered the original results significantly ([Figure 2B](#f2-ott-7-543){ref-type="fig"}). Funnel plot and Egger's test showed no evidence of publication bias (*P*=0.466).

Several studies demonstrated the inconsistent prognostic value of *PIK3CA* mutations in exon 9 and exon 20, thus we performed further meta-analysis in the subgroup of patients with mutations in either exon. Two papers included in the previously pooled mutations analysis also contained data for outcome analysis in exon 9 and exon 20. One paper reporting the results for exon 9 and exon 20, respectively, but without pooled results, was also included. Another eligible paper with data available only for exon 9 was added to the analysis of that subgroup. Therefore, four and three papers were included for analysis of mutations in exon 9 and exon 20, respectively.

[Figure 3A](#f3-ott-7-543){ref-type="fig"} shows the forest plot of meta-analysis of mutations in exon 9. Heterogeneity was statistically significant among the four studies (*I*^2^=68.8%; *P*=0.022). The random effects model was performed, and the combined HR was 1.36 (95% CI: 0.65--2.83; *P*=0.253). To explore the origin of the heterogeneity, we performed sensitivity analysis. This showed that the study by Barbareschi et al substantially impacted the pooled HR ([Figure 3B](#f3-ott-7-543){ref-type="fig"}). After omitting the study, heterogeneity was no longer observed (*I*^2^=0.0%; *P*=0.688) and the revised HR was 0.95 (95% CI: 0.62--1.47; *P*=0.831).[@b13-ott-7-543]

The analysis was repeated for mutations in exon 20 ([Figure 4](#f4-ott-7-543){ref-type="fig"}). The fixed effects model was performed, with a combined HR of 0.98 (95% CI: 0.68--1.42; *P*=0.931). There was no evidence of heterogeneity among studies (*I*^2^=0.0%; *P*=0.899).

Discussion
==========

We performed a systematic review and meta-analysis to clarify the relationship between *PIK3CA* mutations and survival outcome. Eight eligible studies with *PIK3CA* mutation rates ranging from 25.7%--33.4% were included in the analysis. Our study demonstrates that *PIK3CA* mutations are associated with improved clinical outcomes in operable primary breast cancer, but the associations are not statistically significant in the subgroup analysis of mutations in exon 9 or exon 20 of *PIK3CA*.

PI3K is among the most important downstream molecules in the pathway of tyrosine kinase growth factor receptors, and one of the most promising targets for translational research in oncology.[@b33-ott-7-543] Once activated, PI3K can catalyze the phosphorylation of inositol lipids to produce phosphatidylinositol-3,4,5-trisphosphate.[@b34-ott-7-543] Phosphatidylinositol-3,4,5-trisphosphate activates the serine/threonine kinase AKT, which, in turn, regulates several signaling pathways that control cell survival, apoptosis, proliferation, motility, growth, cytoskeletal rearrangement, migration, and cancer metastasis.[@b35-ott-7-543]--[@b38-ott-7-543] Thus the activation of the PI3K/AKT pathway may have pathogenic effects in human cancer, and some of the derangements in the pathway could be candidate targets for therapy.[@b8-ott-7-543],[@b11-ott-7-543],[@b33-ott-7-543],[@b35-ott-7-543]--[@b38-ott-7-543]

The typical form of PI3K is as a heterodimer with an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The 85 kDa regulatory subunit can bind to phosphotyrosine residues of activated growth factors, inducing activation of the lipid kinase activity of the 110 kDa catalytic subunit. The catalytic subunit is encoded by the *PIK3CA* gene, which is amplified, overexpressed, or mutated in several human malignancies, especially in breast cancer.[@b11-ott-7-543],[@b12-ott-7-543],[@b22-ott-7-543] Several studies have reported *PIK3CA* mutation in breast cancer patients, with great inconsistency regarding the association between mutation and clinical outcome.[@b14-ott-7-543]--[@b17-ott-7-543],[@b27-ott-7-543]--[@b30-ott-7-543] A meta-analysis would help to clarify this issue.

In the present study, we have demonstrated that the mutations of *PIK3CA* are associated with better prognosis. Only studies with operable primary breast cancer were included in the analysis. Studies researching metastatic breast cancer or other breast cancers were excluded, considering the many confounding factors that may exist in these patients, which would impair the efficacy of this study. Six eligible studies included in the analysis were without heterogeneity, and the pooled HR was 0.72 (95% CI: 0.57--0.91; *P*=0.006). However, the subgroup analysis of mutations in exon 9 and exon 20 did not achieve the same result with statistical significance. Heterogeneity was significant among the studies in the subset of exon 9. Sensitivity analysis showed that the study by Barbareschi et al[@b13-ott-7-543] seemed to be a major source of heterogeneity. After removing this study, the heterogeneity disappeared, and the combined HR declined from 1.36 to 0.95, still without statistical significance. The disparate results before and after removing this study may be due to the high proportion of lobular tumor in exon 9 *PIK3CA*-mutant patients (33.3% of exon 9 *PIK3CA*-mutant cases were lobular tumor, while the number for the other three studies included in this subgroup analysis were less than 9% or unknown).

Results of the subgroup analysis of exon 9 and exon 20 mutations did not agree with the result from pooled *PIK3CA* mutations. There are a number of possible reasons for this. First, the numbers of studies and patients included in the subgroup analysis were relatively small, and may not be enough to tell the difference between the clinical outcomes. For mutations in exon 9, four studies with 913 patients were analyzed at first. After removing one study (that of Barbareschi et al)[@b13-ott-7-543] for its heterogeneity, the number declined to three studies with 752 patients, which was the same sample size as in the analysis of mutations in exon 20, but less than half the sample size of the pooled *PIK3CA* mutation analysis. The small population could be more vulnerable to confounding factors, making it more difficult to distinguish statistical difference. Second, not all of the studies analyzing the pooled mutations conducted subgroup analyses. The studies by Loi et al[@b17-ott-7-543] and Jensen et al[@b19-ott-7-543] found that the combined mutation analysis did not have statistical significance and further analyzed the subgroups. In other words, studies that analyzed the subgroups tended to report statistical nonsignificance of the combined analysis. This bias could impair the final results of the subgroup meta-analysis. Furthermore, of the three studies included in the subgroup analysis, the study by Loi et al[@b17-ott-7-543] focused on the primary ER+/HER2− breast cancers, while Jensen et al[@b19-ott-7-543] studied HER2+ patients. The effect of *PIK3CA* mutation in different subtypes of breast cancer may vary. Future studies should scrutinize the association of *PIK3CA* mutations with specific molecular subtypes of breast cancer, such as luminal A, luminal B, basal-like, and HER2+ subtypes.

The following limitations of this study should be declared. First, there may be other prognostic factors not controlled in the meta-analysis. The different exons in which the mutations resided, different histologic types of cancer, hormonal receptor status, and HER2 status were not always adjusted in the eligible studies. The effect of the *PIK3CA* mutations on clinical outcomes may vary in patients with different clinicopathological features. However, due to the lack of sufficient patient information, we were unable to conduct sub-analyses according to different features. Second, our meta-analysis was based on data only from studies whose results have been published, and we could not obtain updated data on individual patients. Use of individual patient data could further enhance the accuracy and reduce the uncertainty of our estimates. Third, because we evaluated studies for inclusion through review of title and abstract, studies that did not mention HR and 95% CI in their abstract were excluded, and this may have led to selection bias. Finally, publication bias was also a concern. It was unavoidable that some data would remain unobtainable even after we tried to identify all relevant information. However, after examining the Begg's funnel plots and performing the Egger's linear regression test, we found that the association between *PIK3CA* mutation and clinical outcome remained unchanged.

Conclusion
==========

Our meta-analysis demonstrates the favorable prognostic value of *PIK3CA* mutations in operable primary breast cancer patients. Further studies should investigate the effects of *PIK3CA* mutations on clinical outcome in different histologic types, different molecular subtypes of breast cancer, and different exons of *PIK3CA*.
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![The literature search process.\
**Notes:** One thousand one hundred and eighty studies were identified in the primary literature search. Twenty-six potentially relevant studies were further evaluated and eight studies were finally included in the analysis according to the inclusion criteria.](ott-7-543Fig1){#f1-ott-7-543}

![Individual study and overall HRs of relationships between *PIK3CA* mutations and treatment outcomes.\
**Notes:** The mutations analyzed here included mutations in exon 9 and exon 20, except in the study by Maruyama et al,[@b14-ott-7-543] which also contained mutations in other exons. (**A**) Forest plots; (**B**) Influence of individual studies on the pooled HR.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; *PIK3CA*, p110α catalytic subunit of phosphatidylinositol 3-kinase.](ott-7-543Fig2){#f2-ott-7-543}

![Individual study and overall HRs of relationships between *PIK3CA* mutations in exon 9 and treatment outcomes.\
**Notes:** (**A**) Forest plots. Weights are from random effects analysis; (**B**) Influence of individual studies on the pooled HR.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; *PIK3CA*, p110α catalytic subunit of phosphatidylinositol 3-kinase.](ott-7-543Fig3){#f3-ott-7-543}

![Individual study and overall HRs of relationships between *PIK3CA* mutations in exon 20 and treatment outcomes.\
**Notes:** (**A**) Forest plots; (**B**) Influence of individual studies on the pooled HR.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; *PIK3CA*, p110α catalytic subunit of phosphatidylinositol 3-kinase.](ott-7-543Fig4){#f4-ott-7-543}

###### 

Characteristics of eligible studies

  Study, year                                  Country                       Number of patients                               Median patient age, years                                      Stage        Treatment                     Median follow-up time, months   Sample type   Mutation detection method   Mutation type   Number of *PIK3CA*-mutant patients (%)   Number of mutations in exon 9 (%)   Number of mutations in exon 20 (%)   ER+ (%)[c](#tfn3-ott-7-543){ref-type="table-fn"}   HER2+ (%)[d](#tfn4-ott-7-543){ref-type="table-fn"}   Outcome   Study quality [e](#tfn5-ott-7-543){ref-type="table-fn"}
  -------------------------------------------- ----------------------------- ------------------------------------------------ -------------------------------------------------------------- ------------ ----------------------------- ------------------------------- ------------- --------------------------- --------------- ---------------------------------------- ----------------------------------- ------------------------------------ -------------------------------------------------- ---------------------------------------------------- --------- ---------------------------------------------------------
  Barbareschi et al,[@b13-ott-7-543] 2007      Italy                         161                                              62 (range 17--89)                                              PBC          Chem or horm                  NR                              FTS           SSCP                        Missense        45 (28.0)                                24 (53.3)                           21 (46.7)                            84.4                                               17.8                                                 DFS       8
  Maruyama et al,[@b14-ott-7-543] 2007         Japan                         188                                              NR                                                             PBC          Chem or horm or chem + horm   64 (range 38--88)               FTS           ABI                         Missense        54 (29)                                  17 (31.5)                           29 (53.7)                            77.8                                               18.8                                                 DFS       8
  Kalinsky et al,[@b15-ott-7-543] 2009         USA                           590                                              58 (range 27--89)                                              PBC          NR                            153                             FFPE          ARRAY and SS                Missense        192 (32.5)                               54 (28.1)                           88 (45.8)                            76.2                                               3.6                                                  DFS       7
  Bozhanov et al,[@b16-ott-7-543] 2010         Bulgaria                      145                                              NR (range 29--88)                                              PBC          NR                            69 (range 11--96)               FTS           DS                          Missense        46 (31.7)                                18 (39.1)                           28 (60.9)                            53.3                                               27.8                                                 OS        7
  Loi et al,[@b17-ott-7-543] 2010              USA                           173                                              NR                                                             I--III       Horm                          115                             FTS           SSCP                        Missense        46 (26.6)                                32 (69.6)                           14 (30.4)                            100                                                0.0                                                  DFS       6
  Cizkova et al,[@b18-ott-7-543] 2012          France                        452                                              61.6[b](#tfn2-ott-7-543){ref-type="table-fn"} (range 31--91)   PBC          Chem or horm or chem + horm   120                             FTS           ABI                         Missense        151 (33.4)                               65 (42.8)                           87 (57.2)                            67.8                                               25.2                                                 DFS       8
  Jensen et al,[@b19-ott-7-543] 2012           Denmark                       237                                              NR                                                             I--III       Chem + T or chem + horm + T   67                              FFPE          DiS and PS                  Missense        61 (25.7)                                21 (34.4)                           40 (65.6)                            52.5                                               100                                                  DFS       8
  Ramirez-Ardila et al,[@b20-ott-7-543] 2013   The Netherlands and Belgium   1,352[a](#tfn1-ott-7-543){ref-type="table-fn"}   NR                                                             PBC or ABC   Untreated or endo             NR                              FTS or FFPE   Sna                         Missense        423 (31)                                 173 (40.8)                          251 (59.2)                           91.2                                               9.8                                                  DFS       8

**Notes:**

The study contained three subsets. Only 342 patients with untreated lymph node-negative breast cancer were studied for the relationship between *PIK3CA* mutation and metastasis-free survival

mean age of the study cases

the percentage of ER+ patients in all *PIK3CA*-mutant patients

the percentage of HER2+ patients in all *PIK3CA*-mutant patients

evaluated by the Newcastle-Ottawa Scale.[@b33-ott-7-543] Sequenom MassARRAY^®^: University of Arizona Genetics Core, Tucson, AZ, USA; SNaPshot^®^ Multiplex System: Life Technologies, Carlsbad, CA, USA; ABI automated sequence: Applied Biosystems, Inc., CA, USA.

**Abbreviations:** ABC, advanced breast cancer; ABI, ABI automated sequencer; ARRAY, Sequenom MassARRAY system; chem, chemotherapy; DFS, disease-free survival; DiS, dideoxynucleotide sequencing; DS, direct sequencing; endo, endocrine therapy; ER, estrogen receptor; FFPE, formalin-fixed, paraffin-embedded tissue sample; FTS, frozen tissue sample; HER2, human epidermal growth factor receptor-2; horm, hormonotherapy; NR, not reported; OS, overall survival; PBC, primary breast cancer; *PIK3CA*, p110α catalytic subunit of phosphatidylinositol 3-kinase; PS, pyrosequencing; Sna, SNaPshot Multiplex System sequencing; SS, Sanger sequencing; SSCP, single-strand conformation polymorphism; T, trastuzumab.
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